Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.55 |
| ▸ | CTSA | P10619 | 2/20 | 0.52 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.45 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31226250 | 0.85 | EGLN1 (0.68) | EGLN1CTSAVEGFAFLT1EGLN3 | |
| SCHEMBL1921938 | 0.85 | EGLN1 (0.68) | EGLN1CTSAVEGFAFLT1EGLN3 | |
| SCHEMBL24405150 | 0.84 | EGLN1 (0.49) | EGLN1CTSAVEGFAFLT1EGLN3 | |
| SCHEMBL10274536 | 0.83 | KMT2A (0.50) | CTSAKMT2AMEN1MMP13POLB | |
| SCHEMBL13852609 | 0.82 | KMT2A (0.52) | CTSAKMT2AMEN1MMP13POLB | |
| SCHEMBL107759 | 0.80 | CTSA (0.50) | CTSAKMT2AMEN1MMP13 | |
| SCHEMBL168844 | 0.79 | MAOB (0.51) | CTSAKMT2AMEN1MMP13POLB | |
| SCHEMBL7083262 | 0.79 | CTSA (0.45) | CTSAKMT2AMEN1MMP13POLB | |
| SCHEMBL13602358 | 0.79 | KMT2A (0.53) | CTSAKMT2AMEN1MMP13POLB | |
| SCHEMBL10992192 | 0.79 | EGLN1 (0.56) | EGLN1CTSAEGLN3EGLN2FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7589112-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | EGLN1 1070/4885CTSA 4790/4885VEGFA 3489/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | EGLN1 1070/4885CTSA 4790/4885VEGFA 3489/4885 |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP3K2 | EGLN1 1924/4885CTSA 2358/4885VEGFA 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.